Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
482 Leser
Artikel bewerten:
(2)

SpinChip Diagnostics AS: SpinChip Secures NOK 130 million (€13.5 Million) in Financing Round

Finanznachrichten News
  • The financing round will support further development of SpinChip's proprietary point-of-care in vitro diagnostics platform
  • SpinChip is now preparing for design verification and validation, CE-marking and market entry

OSLO, Norway, June 29, 2021 (GLOBE NEWSWIRE) -- SpinChip Diagnostics AS, a pioneering, diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announced the completion of its financing round, successfully securing NOK 130 million (€13.5 million).

Carnegie Investment Bank Norwayacted as Sole Bookrunner on SpinChip's NOK 130 million (€13.5 Million) private placement. Alongside new cornerstone investors such as Kistefos AS, the financing round was also well supported by existing shareholders.

The proceeds from the financing round will be used to further advance SpinChip's proprietary point-of-care (POC) in vitro diagnostics platform in addition to establishing a pilot- and full-scale manufacturing plant to prepare for market entry.

The SpinChip proprietary diagnostics platform, consisting of the SpinChip Analyser and assay-specific cartridges, is built on microfluidic technology in combination with nanotechnology-based cartridge assays. The platform is aimed at providing patients and healthcare professionals with a tool that only requires one droplet of blood to provide highly accurate results within minutes, next to the patient.

The diagnostics platform has through internal trials already proven to match the most advanced high-sensitive laboratory diagnostic analysers, meaning it can contribute to faster reliable triaging and facilitate earlier onset of appropriate treatment of patients. SpinChip is now preparing for clinical trial activities, including clinical performance studies, to gather sufficient data to apply for CE-marking, with its first diagnostic offering being within the acute cardiac segment.

Morten Jurs, Chief Executive Officer of SpinChip Diagnostics AS, commented:"We are very pleased to have successfully completed the NOK 130 million private placement and are delighted to welcome several new investors to SpinChip, alongside with strong support from existing shareholders. With this financial backing, we will be able to take the platform into the next stage of development to eventually apply for CE-marking whilst we are preparing for market entry."

Stig Morten Borch, Founder and Chief Scientific Officer of SpinChip Diagnostics AS, added:"SpinChip's platform represents the future of POC testing and we are delighted to get additional financial support to further advance the platform at this exciting time for the business."

Contact information:

Morten Jurs, Chief Executive Officer
E-mail: mj@spinchip.no
Phone: +47 991 67 922

Stig Morten Borch, Founder and Chief Scientific Officer
E-mail:smb@spinchip.no
Phone: +47 905 28 151

About SpinChip Diagnostics AS

Representing the future of point-of-care testing, SpinChip Diagnostics was founded in Norway in 2012. SpinChip's proprietary platform is focused on in-vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with life-saving treatments. The platform is based on microfluidic technology in combination with nanotechnology-based cartridge assays, which together can relay test results as accurately as high-sensitive laboratory diagnostic machine within minutes, with only one drop of blood.

Visit Spinchip Diagnostics - Next-generation point-of-care platformfor more information.


© 2021 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.